UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 204

Sortiert nach

Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer's Disease

International journal of molecular sciences, 2023-06, Vol.24 (13), p.10523

2023

Link zum Volltext

Verfügbarkeit prüfen

The challenges of clinical trials in fragile X syndrome

Psychopharmacology, 2014-03, Vol.231 (6), p.1237-1250

2014

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of group-I metabotropic glutamate receptors protects against prion toxicity

PLoS pathogens, 2017-11, Vol.13 (11), p.e1006733

2017

Link zum Volltext

Verfügbarkeit prüfen

Genetic models of cleavage-reduced and soluble TREM2 reveal distinct effects on myelination and microglia function in the cuprizone model

Journal of neuroinflammation, 2023-02, Vol.20 (1), p.29-29, Article 29

2023

Link zum Volltext

Verfügbarkeit prüfen

Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by [11C]-ABP688 PET imaging in healthy volunteers

NeuroImage (Orlando, Fla.), 2021-04, Vol.230, p.117785-117785, Article 117785

2021

Link zum Volltext

Verfügbarkeit prüfen

In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB

Journal of cerebral blood flow and metabolism, 2017-08, Vol.37 (8), p.2716-2727

2017

Link zum Volltext

Verfügbarkeit prüfen

Fractalkine shedding is mediated by p38 and the ADAM10 protease under pro-inflammatory conditions in human astrocytes

Journal of neuroinflammation, 2016-08, Vol.13 (1), p.189-189, Article 189

2016

Link zum Volltext

Verfügbarkeit prüfen

AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome

Neurobiology of disease, 2011-06, Vol.42 (3), p.311-317

2011

Link zum Volltext

Verfügbarkeit prüfen

Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study

Biological psychiatry : cognitive neuroscience and neuroimaging, 2017-07, Vol.2 (5), p.449-456

2017

Link zum Volltext

Verfügbarkeit prüfen

Metabotropic Glutamate Receptors for Parkinson's Disease Therapy

Parkinson's disease, 2013-01, Vol.2013, p.196028-11

2013

Link zum Volltext

Verfügbarkeit prüfen

Development of mavoglurant and its potential for the treatment of fragile X syndrome

Expert opinion on investigational drugs, 2014-01, Vol.23 (1), p.125-134

2014

Link zum Volltext

Verfügbarkeit prüfen

Potential anxiolytic‐ and antidepressant‐like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist

British journal of pharmacology, 2001-04, Vol.132 (7), p.1423-1430

2001

Link zum Volltext

Verfügbarkeit prüfen

Novel allosteric antagonists shed light on mglu5 receptors and CNS disorders

Trends in pharmacological sciences (Regular ed.), 2001-07, Vol.22 (7), p.331-337

2001

Link zum Volltext

Verfügbarkeit prüfen

Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents

The Journal of pharmacology and experimental therapeutics, 2000-12, Vol.295 (3), p.1267

2000

Link zum Volltext

Verfügbarkeit prüfen

The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors

The Journal of biological chemistry, 2000-10, Vol.275 (43), p.33750-33758

2000

Link zum Volltext

Verfügbarkeit prüfen

CPCCOEt, a Noncompetitive Metabotropic Glutamate Receptor 1 Antagonist, Inhibits Receptor Signaling Without Affecting Glutamate Binding

Molecular pharmacology, 1999-03, Vol.55 (3), p.453

1999

Link zum Volltext

Verfügbarkeit prüfen

ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: Identification, in vitro pharmacology, pharmacokinetic and biodistribution studies

Bioorganic & medicinal chemistry, 2007-01, Vol.15 (2), p.903-914

2007

Link zum Volltext

Verfügbarkeit prüfen

The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats

Neuropharmacology, 2001-07, Vol.41 (1), p.1-7

2001

Link zum Volltext

Verfügbarkeit prüfen

Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome

Clinical epigenetics, 2016-02, Vol.8 (15), p.15-15, Article 15

2016

Link zum Volltext

Verfügbarkeit prüfen

The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro

BMC medical genetics, 2012-03, Vol.13 (1), p.13-13, Article 13

2012

Link zum Volltext

Verfügbarkeit prüfen

Increased Seizure Susceptibility in Mice Lacking Metabotropic Glutamate Receptor 7

The Journal of neuroscience, 2001-11, Vol.21 (22), p.8734-8745

2001

Link zum Volltext

Verfügbarkeit prüfen

Effects of the prototypical mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats

European journal of pharmacology, 2000-10, Vol.406 (3), p.403-410

2000

Link zum Volltext

Verfügbarkeit prüfen

Design and Synthesis of Selective and Potent Orally Active S1P5 Agonists

ChemMedChem, 2010-10, Vol.5 (10), p.1693-1696

2010

Link zum Volltext

Verfügbarkeit prüfen

SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5

The Journal of pharmacology and experimental therapeutics, 1999-07, Vol.290 (1), p.170

1999

Link zum Volltext

Verfügbarkeit prüfen

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

Nature reviews. Drug discovery, 2018-04, Vol.17 (4), p.280-299

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 204

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(189)
Mit Volltextzugriff
(185)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(152)
Life Sciences & Biomedicine
(144)
Humans
(102)
Male
(78)
Animals
(63)
Female
(60)
Neurosciences & Neurology
(55)
Neurosciences
(44)
Biological And Medical Sciences
(42)
Pharmacology & Pharmacy
(41)
Medical Sciences
(39)
Receptors, Metabotropic Glutamate - Antagonists & Inhibitors
(37)
Middle Aged
(33)
Aged
(31)
Receptor, Metabotropic Glutamate 5
(30)
Adult
(26)
Neurology
(26)
Rats
(23)
Mice
(22)
Pharmacology. Drug Treatments
(22)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer's Disease

The challenges of clinical trials in fragile X syndrome

Inhibition of group-I metabotropic glutamate receptors protects against prion toxicity

Genetic models of cleavage-reduced and soluble TREM2 reveal distinct effects on myelination and microglia function in the cuprizone model

Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by [11C]-ABP688 PET imaging in healthy volunteers

In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB

Fractalkine shedding is mediated by p38 and the ADAM10 protease under pro-inflammatory conditions in human astrocytes

AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome

Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study

Metabotropic Glutamate Receptors for Parkinson's Disease Therapy

Development of mavoglurant and its potential for the treatment of fragile X syndrome

Potential anxiolytic‐ and antidepressant‐like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist

Novel allosteric antagonists shed light on mglu5 receptors and CNS disorders

Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents

The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors

CPCCOEt, a Noncompetitive Metabotropic Glutamate Receptor 1 Antagonist, Inhibits Receptor Signaling Without Affecting Glutamate Binding

ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: Identification, in vitro pharmacology, pharmacokinetic and biodistribution studies

The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats

Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome

The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro

Increased Seizure Susceptibility in Mice Lacking Metabotropic Glutamate Receptor 7

Effects of the prototypical mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats

Design and Synthesis of Selective and Potent Orally Active S1P5 Agonists

SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

Suchergebnisse filtern